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Abstract: Achiral Mannich-type curcumin analogs have been synthetized and assayed for their
cytotoxic activity. The anti-proliferative and cytotoxic activity of curcuminoids has been tested on
human non-small-cell lung carcinoma (A549), hepatocellular carcinoma (HepG2) and pancreatic
cancer cell line (PANC-1). Based on the highest anti-proliferative activity nine drug candidates
were further tested and proved to cause phosphatidylserine exposure as an early sign of apoptosis.
Curcumin analogs with the highest apoptotic activity were selected for mechanistic studies in
the most sensitive PANC-1 cells. Cytotoxic activity was accompanied by cytostatic effect since
curcumin and analogs treatment led to G0/G1 cell cycle arrest. Moreover, cytotoxic effect could
be also detected via the accumulation of curcuminoids in the endoplasmic reticulum (ER) and
the up-regulation of ER stress-related unfolded protein response (UPR) genes: HSPA5, ATF4,
XBP1, and DDIT3. The activated UPR induced mitochondrial membrane depolarization, caspase-3
activation and subsequent DNA breakdown in PANC-1 cells. Achiral curcumin analogs, C509,
C521 and C524 possessed superior, 40-times more potent cytotoxic activity compared to natural
dihydroxy-dimetoxycurcumin in PANC-1 cells.
Keywords: curcumin; endoplasmic reticulum stress; unfolded protein response; mitochondrial
depolarization; caspase-3; apoptosis
1. Introduction
Turmeric spice obtained from the rhizomes of Curcuma longa has been used for centuries in
traditional Chinese medicine and in Ayurveda in India based on its assumed anti-inflammatory,
anti-microbial, and anti-cancer effects [1]. Curcuminoids make up 2–5% of turmeric powder and
consist of dihidroxy-dimetoxycurcumin (curcumin, 77%), mono-demethoxycurcumin (17%) and
bis-demethoxycurcumin (3%) [2]. Due to the empirical beneficial health effect of turmeric the
consumption of curcumin as a dietary supplement increased worldwide. By today, curcumin has
been designated “Generally Recognized as Safe (GRAS)” by the Food and Drug Administration of
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the United States [3]. The widespread consumption of turmeric and curcumin and its potential as a
pharmaceutical laid down the basis for the need of proper scientific studies to reveal the effects of
curcumin on human health as well as the design and synthesis of curcumin analogs which can be
potentially introduced to the clinic. Our aim was to increase the cytotoxicity of Mannich-type curcumin
analogs and reveal their mechanism of action in a cellular system.
Tumorigenesis is a multistep process in which curcumin has been implicated to suppress the
growth of tumor cells by reducing their proliferation and survival as well as to induce tumor cell
death [2,4,5]. It has been published that curcumin inhibited the proliferation and induced the apoptosis
of non-small-cell lung carcinoma cells (A549 cell line) by the up-regulation of microRNA-192-5p and
suppression of the PI3K3/Akt signaling pathway [6]. In another study apoptosis of A549 cells induced
by curcumin relied on oxidative stress and Mitogen-activated protein kinase (MAPK) pathway [7].
Curcumin attenuate not only tumor cell viability but also the metastatic ability of A549 cells by blocking
the adiponectin receptor 1 [8] and glucose transporter 1 (GLUT1) [9]. Therefore, we tested our novel
curcumin analogs on the non-small cell lung cancer (NSCLC) cell line, A549.
Curcumin caused apoptosis of human hepatocellular carcinoma HepG2 cells as well, via
disruption of mitochondrial membrane potential [10] and counteracted fatty acid synthase [11]. In our
study, we tested our analogs on both A549 cells as well as on the hepatocellular carcinoma (HCC) cell
line HepG2.
Finally, we focused on PANC-1 cells, because among solid tumors, pancreatic malignancy has the
highest mortality rate with the overall 5-year survival being less than 6% [12]. The possible application
of curcumin in pancreatic cancer has been reported earlier where the authors showed that PANC-1
cells were sensitive to curcumin treatment via reduction of the inhibitors of apoptosis [13] and through
the induction of forkhead box O1 [14].
Here, we present achiral Mannich-type curcumin analogs with potential cytotoxic activity on
human NSCLC, hepatocellular carcinoma, and pancreatic cancer cell lines.
2. Results and Discussion
2.1. Achiral Curcumin Analogs Impaired Tumor Cell Viability
Recently, we have reported the potent cytotoxic activity of racemic Mannich-type curcumin
analogs [15–17]. Here, we report the cytotoxic activity of the achiral curcumin analog library (C500
series) (Figure 1 and Figure S1).
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The substitution pattern was carefully chosen based on the already established structure-activity
relationship (SAR) results [17], with the ultimate aim to design a simpler and achiral library of
curcuminoids with an improved pharmacokinetic profile. All intermediates and compounds were
synthesized based on the previously established method [17,18]. As a pre-screening we tested the
anti-proliferative effect of the first analog, C501 by measuring the confluency by live cell analyzer of
C501 treated A549 cells (Figure S2). Since the anti-proliferative activity of C501 reached its maximum
effect at 3.125 µM, we used lower concentrations of the members of C500 series (0.16–5 µM) in the
subsequent experiments. We defined the dose-response curves of the 23 members of C500 series
by the significantly more sensitive resazurin assay on A549, HepG2, and PANC-1 cells (Figure S3).
The half maximal inhibitory concentration (IC50) values are presented in Table 1. The IC50 value of
curcumin was above the pharmacologically favorable range 27.11 µM, 14.53 µM, and 30.57 µM in
A549, HepG2, and PANC-1 cells, respectively. Six molecules were completely inactive at the applied
concentrations (C514, C520, C525, C526, C529, and C530) and were not tested further. This was in
full accordance with previously established SAR results [17,18], that the presence of functionalities
such as carboxylic acid, dihydroxyphenyl, or para-hydroxy substituents resulted in the complete loss
of cytotoxic activity. Compounds which possessed low anti-proliferative activity (IC50 > 5 µM) were
also excluded from further testing (C502, C510, C513, C516, C517, C519, C532, and C533). The current
project focused on curcumin analogs with potent cytotoxic activity on three different cell lines: A549,
HepG2, and PANC-1. Nine of the 23 novel curcumin analogs (C501, C503, C504, C505, C509, C515,
C518, C521, and C524) hampered the viability of all three tested cell lines when used below 5 µM.
Table 1. IC50 values (µM) of curcumin (Curc.) and curcumin analogs determined by resazurin assay.
Compound A549 HepG2 PANC-1
Curc. 27.11 14.53 30.57
C501 # 1.26 0.66 1.44
C502 2.39 >5 2.20
C503 # 1.70 2.55 1.66
C504 # 1.58 1.24 1.40
C505 # 1.29 1.48 1.43
C509 # 2.27 2.98 1.01
C510 >5 1.07 >5
C513 >5 3.11 >5
C514 inactive inactive inactive
C515 # 2.73 1.31 1.46
C516 >5 4.19 >5
C517 >5 >5 2.45
C518 # 2.42 4.77 1.25
C519 >5 >5 >5
C520 inactive inactive inactive
C521 # 1.88 1.36 1.18
C524 # 1.70 1.69 1.14
C525 inactive inactive inactive
C526 inactive inactive inactive
C529 inactive inactive inactive
C530 inactive inactive inactive
C532 >5 >5 1.58
C533 >5 4.81 >5
Cells were treated with curcumin (1.56, 3.125, 6.25, 12.5, 25, and 50 µM) and curcumin analogs (0.16, 0.3125, 0.625,
1.25, 2.5, and 5 µM) in duplicates for 72 h. Viability was examined by resazurin assay as described in Section 3.2.
Materials and Methods. Hashmark (#) labeled curcumin analogs were selected for further investigation.
2.2. Curcumin Analogs Induced Phosphatidylserine Exposure of A549, HepG2 and PANC-1 Cells
In order to clarify whether the viability of A549, HepG2, and PANC-1 cells was hampered by
apoptosis or necrosis, we carried out annexin V-propidium iodide (PI) staining on the cells treated by
Int. J. Mol. Sci. 2017, 18, 2105 4 of 16
the nine selected candidates. Curcumin and its analogs showed dose dependent phosphatidylserine
exposure that suggests potent apoptotic activity (AnnV+/PI early apoptosis and AnnV+/PI+ late
apoptosis) in A549 (Figure 2A), HepG2 (Figure 2B), and PANC-1 cells (Figure 2C) without the
appearance of a massive, only PI positive necrotic population (Figure S4).
Int. J. Mol. Sci. 2017, 18, x  4 of 16 
 
described in Section 3.2. Materials and Methods. Hashmark (#) labeled curcumin analogs were 
selected for further investigation. 
2.2. Curcumin Analogs Induced Phosphatidylserine Exposure of A549, HepG2 and PANC-1 Cells 
In order to clarify whether the viability of A549, HepG2, and PANC-1 cells was hampered by 
apoptosis or necrosis, we carried out annexin V-propidium iodide (PI) staining on the cells treated 
by th  nine selecte  candidates. Curcumi  and its analogs showed dose depende t 
phosphatidylserine xposure th t suggests potent apoptotic activity (AnnV+/PI⁻ early apoptosis and 
AnnV+/PI+ late apoptosis) in 549 (Figure 2A), HepG2 (Figure 2B), and PANC-1 cells (Figure 2C) 
without th  appearance of a massive, only PI positive necr tic population (Figure S4). 
 
Figure 2. Curcumin and analogs induced phosphatidylserine exposure on tumor cells. A549 (A), 
HepG2 (B), and PANC-1 (C) cells were incubated with curcumin (Curc.) and curcumin analogs with 
the indicated concentrations (µM) as described in Section 3.3.1. Materials and Methods. The results 
are shown as arithmetic mean values of the summary of early (AnnV+/PI−, gray column) and late 
apoptosis (AnnV+/PI+, white column) of two samples ±SD, * p < 0.05, ** p < 0.01, *** p < 0.001. 
In order to identify the most active analogs, we summarized the percentage of total apoptotic 
cell populations at the lowest applied concentration for each analog in Table 2. Three compounds 




as arith etic ean values of the summary of early (An V+/ I , r )
PI+, white column) of two samples ±SD, * p < 0.05, ** p < 0.01, *** p < .001.
In order to identify the most active analogs, we summarized the percentage of total apoptotic
cell populations at the lowest applied concentration for each analog in Table 2. Three compounds
stood out with appreciable activity, C509, C521, and C524, therefore only these were included in
further experiments. All three molecules share the common C-4 chloroacetamidomethyl and either the
meta-hydroxy or methoxy substituents on their side-chains. An analog with moderate activity, was also
included (C501) in our analyses. Since PANC-1 cells were the most sensitive in our study, additionally
the 5-year overall survival has been reported to be the lowest for pancreatic cancer (less than 6%)
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among other solid malignancies [12], we used PANC-1 cells for subsequent mechanistic studies to
reveal how novel curcumin analogs counteract cancer cell viability.
Table 2. The percentage of apoptotic cells at the lowest applied concentration of 12.5 µM curcumin and
1.25 µM curcumin analogs.
Compound A549 HepG2 PANC-1
None 2.4 ± 0.44 2.7 ± 0.37 1.8 ± 0.02
Curcumin 3.0 ± 0.30 2.0 ± 0.14 7.0 ± 0.02
C501 # 1.3 ± 0.06 2.6 ± 0.55 6.3 ± 0.42
C503 1.9 ± 0.83 2.6 ± 0.33 6.1 ± 0.54
C504 2.0 ± 0.16 3.4 ± 0.28 8.8 ± 1.36
C505 1.8 ± 0.11 5.6 ± 0.31 8.2 ± 5.83
C509 # 2.7 ± 0.25 15.4 ± 9.92 51.0 ± 1.17
C515 3.0 ± 0.77 3.1 ± 0.11 22.5 ± 4.43
C518 3.0 ± 0.01 3.6 ± 0.33 11.8 ± 2.49
C521 # 2.5 ± 0.5 8.9 ± 0.13 37.8 ± 10.86
C524 # 19.8 ± 3.81 7.3 ± 0.37 80.4 ± 0.13
Phosphatidylserine exposure was examined as described in Section 3.3.1. Materials and Methods. Analogs labeled
with a hashmark (#) were selected for further investigation, (± refers to standard deviation)
2.3. Curcumin Analogs Caused G0/G1 Cell-Cycle Arrest of PANC-1 Cells
In addition to cytotoxicity, we also investigated the cytostatic effect of our curcumin analogs on
PANC-1 cells. Curcumin (25 µM), and C509, C521, and C524 (both 1.25 µM) significantly increased
G0/G1 population of PANC-1 cells (up to 80%) compared to the untreated control cells (40%) (Figure 3
and Figure S5).
According to several reports it is unequivocal that curcumin can dysregulate the cell cycle. It has
been reported that natural curcumin caused G2/M mitotic catastrophy, in relation to the G2/M
phase in head and neck squamous cell carcinoma or in bovine aortic endothelial cells after 24 h
incubation [19,20], it was also shown that curcumin caused not only G1/S but also G0/G1 cell cycle
arrest in human prostate cancer cells [21,22]. The differences in cell cycle dysregulation may be
cell type specific or may depend on the different experimental conditions, incubation time period,
the concentration and formulation of curcumin.
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2.4. Curcumin Analogs Induced ER (Endoplasmic Reticulum) Stress and Mitochondrial Membrane
Depolarization
Among others, we have previously shown that perturbing the homeostasis of the ER could reduce
cellular viability [23]. It was recently published that natural curcumin caused ER stress mediated
apoptosis in cervical cancer cells [24] and in A549 cells [7]. In order to clarify whether the apoptotic
effect of curcumin analogs in PANC-1 cells relied on the ER stress related mitochondrial apoptotic
pathway, we followed the accumulation of the tested agents. Since curcumin possesses inherent
fluorescence [25] and our analogs retained this property, we tested the subcellular localization of
curcumin and our analogs in PANC-1 cells by fluorescence confocal microscopy. Similarly to curcumin,
our analogs localized in the ER which was further verified by ER tracker co-localization (Figure 4).
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Figure 4. Curcumin and analogs localized in the endoplasmic reticulum of PANC-1 cells. Cells were
treated with curcumin and analogs (A–E), 1 µM and 5 min. The subcellular localization of curcumin
and its analogs was assessed with endoplasmic reticulum (ER) tracker co-localization by laser scanning
confocal microscopy. To further minimize channel crosstalk, only curcumin analog labeled samples
were also prepared (inset images) and used as reference for image capturing conditions for curcumin-ER
tracker dual labelled samples. Representative images are shown. Scale bar at C524 inset image is valid
for all insets (controls). Scale bar at the lower right corner of C524 is valid for all ER co-localization
images. Both scale bars are 20 µm.
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The subcellular localization of curcumin analogs in the ER may activate an adaptive response
to ER stress known as the unfolded protein response (UPR), which up-regulates ER chaperons, halts
translation of secretory proteins, and degrades misfolded proteins. If the ER stress is irreversible
the UPR mediates apoptotic cell death to restore the cell homeostasis [26]. ER stress was monitored
by the induction of UPR related genes: HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5),
ATF4 (Activating Transcription Factor 4), XBP1 (X-Box Binding Protein 1), and DDIT3 (DNA Damage
Inducible Transcript 3). HSPA5 is a chaperon, master regulator of the UPR [27], ATF4, and XBP1 are
transcriptional activators of UPR genes and chaperons [28], DDIT3 (encoding CHOP) is a transcription
factor mediating ER stress related apoptosis [17,26,29].
Curcumin and the tested analogs induced the expression of all tested genes 12 h after treatment
(Figure 5). The up-regulation of HSPA5 was two-fold by 12.5 µM curcumin and around 10-fold by
1.25 µM C509, C521, and C524 treatment. ATF4 and XBP1 were around 4–5-fold up-regulated upon
curcumin and curcumin analog stimulation. The highest increase was detected in case of DDIT3,
where a 13-fold increase was detected with curcumin (25 µM), while the analogs induced around
30-fold overexpression at 1.25 µM, only C501 showed 60-fold change at 5 µM. DDIT3 overexpression
may suggest that in curcumin and curcumin analog treated cells the UPR progressed to a state
where homeostasis cannot be restored and the cells are committed to an apoptotic fate [29,30].
The concentration dependent decline of gene expression changes (50 µM curcumin and 5 µM C509,
C521, and C524) may be due to the advanced apoptotic program.
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Figure 5. Curcumin analogs induced unfolded protein response during ER stress. Gene expression of
unfolded protein response genes: HSPA5, ATF4, XBP1, DDIT3 (arithmetic means of fold changes ±SD)
in PANC-1 cells treated with curcumin and curcumin analogs after 12 h. Gene expression was analyzed
by qRT-PCR (quantitative real-time polymerase chain reaction) as described in the Section 3.5. Materials
and Methods, * p < 0.05, ** p < 0.01, *** p < 0.001.
Int. J. Mol. Sci. 2017, 18, 2105 8 of 16
The perturbation of the homeostasis of the ER by curcumin analogs may confound the
subcellular oxidative homeostasis affecting mitochondrial membrane potential (MMP) [31]. Therefore,
mitochondrial membrane depolarization was examined by JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolocarbocyanine iodide) staining following curcumin and curcumin analog
treatment of PANC-1 cells. Not only curcumin but also our analogs depolarized mitochondria of
PANC-1 cells in a concentration dependent manner (Figure 6). The effect of curcumin on MMP was
significant at 50 µM, while C501 analog was effective at 5 µM, C509 at 2.5 µM, and C521 and C524
at 1.25 µM.
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Figure 6. Curcumin and analogs depolarized mitochondria of PANC-1 cells examined by JC-1 staining.
(A) Representative SSC-FSC and FL2-FL1 dot plots and (B) arithmetic means of percentages (±SD) of
cells with decreased MMP at 24 h following treatment (µM). JC-1 was analyzed by flow cytometry as
described in Section 3.3.4. Materials and Methods, * p < 0.05, ** p < 0.01, *** p < 0.001.
2.5. Curcumin Analogs Induced Caspase-3 Activation and DNA Fragmentation
Mitochondrial membrane depolarization may lead to the activation of caspases which renders
cells for apoptosis [32]. Effector caspase-3 activation occurred in PANC-1 cells following curcumin
and curcumin analog treatment in a concentration dependent manner (Figure 7). Among curcumin
analogs C524 showed the highest induction of caspase-3 at 5 µM.
Apoptosis executed by the activation of caspases results in the internucleosomal degradation of
genomic DNA which can be studied by flow cytometry as a hypodiploid sub-G1 fraction of the cell
population [33]. In order to confirm that event we analyzed the percentage of cells with degraded
DNA content (Figure 8A). Using PANC-1 cells, our results showed that treatment with curcumin
resulted in DNA degradation at 25 µM, while curcumin analogs exerted a significant effect at 1.25 µM.
Cytotoxicity of the curcumin analogs resulted in DNA breakdown as the final step of apoptosis in a
concentration dependent manner (Figure 8B).
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3. Materials and Methods
3.1. Cell Culturing and Treatments
Cells were purchased from the American Type Culture Collection (ATCC, Manassas, Virginia,
USA). A549, HepG2 cells were maintained in Dulbecco’s Modified Eagle Mediu /Nutrient Mixture
F-12 (DMEM/F12) 10% fetal calf serum (FCS, Gibco) and PANC-1 cells were maintained in Roswell Park
Memorial Institute 1640 medium (RPMI-1640) 10% FCS, pH of the cell culture media was controlled
to be between 7.2–7.4 prior use. Media were supplemented with 2 mM GlutaMAX, and 100 U/mL
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penicillin, 100 µg/mL streptomycin (Life Technologies, Carlsbad, California, USA). The cell cultures
were maintained at 37 ◦C in a humidified incubator in an atmosphere of 5% CO2 (Sanyo, Japan).
Curcumin and curcumin analogs were dissolved in dimethyl sulfoxide (DMSO) at 10 mM
concentration. Since DMSO can be toxic for cellular systems, the stock solution was further diluted in
serial dilutions in all cases in the appropriate cell culture media. The intermediate dilution of curcumin
was 250 µM (40× dilution), it was serially diluted to 125 µM (80× dilution) and it was further diluted
to 62.5 µM (160× dilution), then each intermediate dilution was further diluted 5× when it was added
to the cells, so the treatments of curcumin were 50 µM (200×), 25 µM (400×) and 12.5 µM (800×).
The intermediate dilution of curcumin analogs was 25 µM (400×), it was serially diluted to 12.5 µM
(800× dilution) and it was further diluted to 6.25 µM (1600× dilution), then each intermediate dilution
was further diluted 5× when it was added to the cells so the treatments of curcumin analogs were
5 µM (2000×), 2.5 µM (4000×), and 1.25 µM (8000×).
3.2. Resazurin Viability Assay
The viability of A549, HepG2, and PANC-1 cells was determined by the fluorescent resazurin
assay as described previously [34]. Briefly, cells (6 × 103) were seeded into 96-well plates (Corning Life
Sciences, Tewksbury, MA, USA) in media. Cells were cultured overnight before treatment. Viability was
determined after a 72 h incubation in treated and non-treated cells. Resazurin reagent (Sigma-Aldrich)
was dissolved in phosphate buffered saline (PBS, pH 7.4) at 0.15 mg/mL concentration, sterile filtered
(0.22 µm, Merck Millipore) and aliquoted at −20 ◦C. Samples were treated in 120 µL volume with a
final concentration of 25 µg/mL resazurin. After 2 hours incubation at 37 ◦C 5% CO2, fluorescence
(530 nm excitation/580 nm emission) was recorded on a multimode microplate reader (Cytofluor4000,
PerSeptive Biosytems, Framingham, MA, USA). Viability was calculated in relation to untreated control
cells and blank wells containing media without cells. The presented IC50 values (half maximal inhibitory
concentration) were determined based on dose-response curves plotted in GraphPad Prism® 5 (La Jolla,
CA, USA).
3.3. Flow Cytometry
3.3.1. Detection of Phosphatidylserine Exposure
Cells (5 × 104) were plated in 24-well tissue culture plates (Corning Life Sciences) and treated
in 500 µL volume with increasing concentrations of test compounds in duplicates. After 72 h the
supernatants were harvested. Cells were washed with PBS, trypsinized, pooled with the corresponding
supernatant and pelleted by centrifugation (2000 rpm, 5 min). The pellet was resuspended in annexin V
binding buffer (0.01 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 0.14 M NaCl and
2.5 mM CaCl2). Annexin V-Alexa Fluor® 488 (AnnV, Life Technologies, 2.5:100) was added to the cells,
which were then kept in the dark at room temperature for 15 min. Propidium iodide (PI, Sigma-Aldrich,
St. Louis, MO, USA) was added at a final concentration of 10 µg/mL right before the acquisition of
samples. Cells (2 × 104 events) were analyzed on a FACSCalibur flow cytometer using CellQuest
software (Becton Dickinson, Franklin Lakes, NJ, USA). The percentage of annexin V-Alexa Fluor®
488 positive (FL1 channel, 530/30 nm filter) and propidium iodide negative (FL3 channel, 670 nm
filter) early apoptotic cells and FL1 positive and FL3 positive late apoptotic cells were determined.
The total apoptotic population includes both early and late apoptotic cells. Bar graphs were created by
GraphPad Prism® 5.
3.3.2. Cell Cycle and Sub-G1 Analysis
PANC-1 cells (5 × 104) were plated in 24-well tissue culture plates (Corning Life Sciences) in
RPMI 10% FCS and were treated in 500 µL media containing test compounds in duplicates. After
72 h the supernatant was harvested. Cells were washed with PBS, trypsinized, pooled with the
corresponding supernatant and centrifuged (2000 rpm, 5 min). Pellet was resuspended in DNA
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binding buffer (1× PBS, 0.1% tri-sodium-citrate, 10 µg/mL PI, 0.1% Triton X-100, 10 µg/mL RNase A,
(Sigma-Aldrich)). After incubation at room temperature for 30 min 2 × 104 events were acquired
on a FACSCalibur flow cytometer (Becton Dickinson). Sub-G1 apoptotic population was analyzed
on FL3 histograms using CellQuestTM software (Becton Dickinson). We gated out doublets for cell
cycle analysis which was based on FL2-A/FL2-W dot plots, using Modfit software (Becton Dickinson).
Bar graphs were created by GraphPad Prism® 5.
3.3.3. Immunofluorescence
PANC-1 cells (1 × 105) were plated in 24-well tissue culture plates (Corning Life Sciences)
in RPMI 10% FCS and were treated in 500 µL media containing test compounds. After 72 h the
supernatant was harvested. Cells were washed with PBS, trypsinized, pooled with the corresponding
supernatant and centrifuged (2000 rpm, 5 min). Pellet was resuspended and fixed in 3.5% PBS buffered
formaldehyde (Molar Chemicals) for 10 min. Cells were washed with FACS-buffer (2% FCS in PBS),
centrifuged (2000 rpm, 5 min). Cells were permeabilized in permeabilization buffer (1% FCS, 0.1%
saponin (Sigma-Aldrich) in PBS pH 7.4) for 5 min. Cells were washed with FACS buffer (2% FCS
in PBS), centrifuged (2000 rpm, 5 min). Rabbit polyclonal anti-cleaved caspase-3 antibody (9661S,
Cell Signaling) was added at 1:600 dilution in FACS buffer. After incubation for 1 h at 4 ◦C samples
were washed two times with FACS buffer. The secondary antibody, polyclonal goat anti-rabbit IgG
conjugated with Alexa Fluor® 488 (A11008, Thermo Fisher Scientific, Waltham, MA, USA) was diluted
to 1:600 and incubated with the cells for 30 min at 4 ◦C. After washing, 300 µL FACS buffer was added
for acquisition with the FACSCalibur flow cytometer acquiring 2 × 104 events at FL1 channel. Data
were analyzed using CellQuestTM software (Becton Dickinson) gating out debris. In order to calculate
the signal to noise ratio, median fluorescence intensity (MFI) was calculated by the following equation:
MFI = 10[(Median stained −Median unstained, untreated)/Chd], where Chd (the number of channels per decade)
equals 256, [35,36]. Bar graphs were created by GraphPad Prism® 5.
3.3.4. Detection of the Loss of Mitochondrial Membrane Potential
PANC-1 cells (1× 105) were plated in 24-well tissue culture plates (Corning Life Sciences) in RPMI
10% FCS and were treated in 500 µL media containing test compounds. After 24 h, the supernatants
were harvested. Cells were washed with PBS, trypsinized, pooled with the corresponding supernatant
and centrifuged (2000 rpm, 5 min). Pellet was resuspended and incubated for 15 min in 5 µg/mL
JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide, Chemodex) containing
media in final volume 300 µL at 37 ◦C. Finally, using FL2 (585/42 nm)-FL1 (530/30 nm) channels,
the red–green fluorescence intensity of 1 × 104 events was acquired immediately on FACSCalibur
flow cytometer. Data were analyzed using CellQuestTM software (Becton Dickinson) gating out debris.
Bar graphs were created by GraphPad Prism® 5.
3.4. Confocal Laser Scanning Microscopy
PANC-1 cells (2 × 105) were plated on µ-Slide 8 Well Glass Bottom dishes (Ibidi®,Martinsried,
Germany) in 500 µL media and placed in a humidified incubator at 37◦ C 5% CO2. After 24 h
culturing, detection of curcumin, curcumin analogs (1 µM, 5 min) and ER tracker green (1 µM,
5 min, Thermo Fisher) were performed using Olympus Fluoview FV1000 confocal laser scanning
microscope (Olympus Life Science Europa GmbH, Hamburg, Germany ) in triplicates. Microscope
configuration was the following: objective: UPLFLN 40× (oil, NA:1.3); dichroic mirror: 20/80,
excitation: 405 nm (curcumin analogs), 514 nm (ER tracker); detection range: 425–475 nm (curcumin),
530–630 nm (ER tracker); scanning dimensions: 512 × 512 pixel; sampling speed: 2 µs/pixel; confocal
aperture: 182 µm; zoom: 5×; line averaging: 2×. Curcumin analogs and ER tracker green images
were pseudocolored as cyan and green, respectively. Transmitted light images were also captured with
514 nm laser and paired with each fluorescence image. ER tracker green imaging was performed using
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514 nm laser instead of 488 nm laser to minimize channel crosstalk. Composite images were prepared
using CorelDraw® Graphics Suite X7 (Corel, Ottawa, Canada).
3.5. Gene Expression Analysis
PANC-1 cells (2 × 106) were plated in 60 mm tissue culture dishes (Corning Life Sciences) in
RPMI 10% FCS. Twenty-four hours later cells were treated in 5 mL volume with test compounds. After
12 h treatment, nucleic acid preparation was done by using the Bioneer RNA purification kit (Bioneer,
Viral RNA extraction kit, Daejeon, South Korea) according to an already published protocol [37] with
modifications [38]. The quality and quantity of the isolated RNA were measured with NanoDrop1000
Version 3.8.1. (Thermo Fisher Scientific).
Reverse transcription from 3 µg of total RNA was performed with the High-Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, California, USA) in a total volume of 30 µL according
to the manufacturer’s protocol. After dilution with 130 µL of ultrapure water (Applied Biosystems)
cDNA was used as template for gene expression analysis. Quantitative real-time PCR (qRT-PCR)
was performed on the LightCycler®Nano Instrument (Roche, Basel, Switzerland) using gene-specific
primers with SYBR Green protocol as described previously [38]. Briefly: for cycling each 10 µL PCR
reaction contained 1 µL cDNA, 250 nM primers and 5 µL FastStart Essential DNA Green Master
(2×, Roche). Primers were as follows:
Heat Shock Protein Family A (Hsp70) Member 5 (HSPA5, NM_005347.4), HSPA5-F
5′-AGCCTGGCGACAAGAGTG-3′, HSPA5-R 5′- TCCTTGGGCAGTATTGGATT-3′; the following
primer sequences are referenced by [17]: Activating Transcription Factor 4 (ATF4, NM_182810.2,
NM_001675.4), X-Box Binding Protein 1 (XBP1, NM_005080.3, NM_001079539.1), DNA Damage
Inducible Transcript 3 (DDIT3, NM_004083.5, M_001195056.1, NM_001195055.1, NM_001195054.1,
NM_001195053.1), β-actin (ACTB, BC002409.2).
The PCR protocol was as follows: enzyme activation at 95 ◦C for 10 min, 45 cycles of denaturation
at 95 ◦C for 15 s, annealing at 60 ◦C and extension at 72 ◦C for 25 s. All the PCRs were performed with
three replicates. After amplification, melting curve was checked to verify the specificity of the PCR
reactions. The presented relative gene expression ratios were normalized to ACTB gene, calculated
using the comparative CT method (2−∆∆CT). Fold change refers to 2−∆∆Ct treated/2−∆∆Ct untreated.
All values are presented as mean ± standard deviation (SD).
3.6. Statistical Analysis
Statistical analysis was performed using two-tailed, homoscedastic Student’s t-test to evaluate the
statistical significance (set at * p < 0.05, ** p < 0.01, *** p < 0.001) using pairwise comparison of each
sample to the untreated control in Microsoft® Excel™.
4. Conclusions
Despite the emerging field of targeted anti-cancer therapeutics the combination of different
therapeutic strategies (surgery, radiation, chemotherapeutic agents, biologics and immunotherapy etc.)
may combat cancer and mount an effective therapeutic response [39–42], however, there is a high need
for novel anti-cancer agents with improved cancer cell killing with less side effects.
We designed and synthetized a library of twenty-three achiral curcumin analogs to follow up on
our previous work to identify potent, cytotoxic Mannich-base curcuminoids [15,17]. These compounds
lack a chiral center so their biological/pharmacological testing is more straightforward without the
need for the evaluation of the individual enantiomers. We tested the anti-proliferative activity of our
curcumin analogs on human non-small-cell lung carcinoma (A549), hepatocellular carcinoma (HepG2),
and pancreatic cancer (PANC-1) cell lines.
Three curcuminoids, C509, C521, and C524 with the highest apoptotic activity were selected
for mechanistic studies in the most sensitive PANC-1 cells. We found that the biological activity
of the analogs on one hand relied on a cytostatic effect since curcumin and curcuminoid analog
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treatment led to G0/G1 cell cycle arrest. On the other hand, our compounds also possessed a potent
cytotoxic effect (Figure 9). Their accumulation in the ER caused ER stress, the induction of the unfolded
protein response, mitochondrial membrane depolarization, caspase-3 activation, and subsequently
DNA breakdown.
Three curcumin analogs, C509, C521, and C524 possessed superior, 40-times more potent cytotoxic
activity compared to the natural dihydroxy-dimetoxycurcumin in human pancreatic cancer cells,
offering the possibility for their further investigation.
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